Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
210.9 USD | -0.75% | -0.99% | +0.16% |
Apr. 26 | Wall Street: the worst week of 2024 is followed by the best | CF |
Apr. 26 | US Equity Indexes Advance This Week as Fed's Preferred Measure of Inflation Meets Expectations | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The firm trades with high earnings multiples: 22.17 times its 2024 earnings per share.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Financial & Commodity Market Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.16% | 75.94B | B | ||
+12.06% | 21.7B | C+ | ||
+27.19% | 12.54B | C+ | ||
+39.83% | 8.36B | C+ | ||
+44.53% | 5.21B | C | ||
-2.16% | 2.96B | C+ | ||
+30.25% | 2.55B | C | ||
-5.45% | 1.69B | C | ||
+15.14% | 1.29B | - | ||
+74.10% | 1.28B | - | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CME Stock
- Ratings CME Group Inc.